drug_type
RELEVANT_DRUG
intervention_type
cellular immunotherapy (autologous TIL)
drug_description
Autologous tumor-infiltrating lymphocyte (TIL) cell therapy in which patient tumor T cells are expanded ex vivo and reinfused after lymphodepleting chemotherapy to mediate tumor-specific cytotoxicity and enhance persistence.
nci_thesaurus_concept_id
C199290
nci_thesaurus_preferred_term
Autologous Tumor Infiltrating Lymphocytes C-TIL051
nci_thesaurus_definition
A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patients resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs C-TIL051 specifically recognize and kill the patients tumor cells.
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells isolated from the patient’s tumor are expanded ex vivo and reinfused after lymphodepleting chemotherapy to reconstitute a large pool of tumor‑reactive T cells. These TILs recognize native tumor antigens via their endogenous TCRs and mediate tumor cell killing through cytotoxic effector functions, supporting durable antitumor immunity.
drug_name
C-TIL051
nct_id_drug_ref
NCT05676749